Neutrophils and Monocytes in Pediatric Ischemic Stroke

项目总结(说明) 大约每1600到4000名新生儿中就有1人受到缺血性中风的影响，新生儿和婴儿的发病率最高(&lt； 一岁)，并可能导致神经后遗症，包括运动和认知障碍。感染和 免疫反应是儿童中风的主要危险因素，但目前还没有针对免疫的治疗方法。 事实上，支持性措施仍然是儿科卒中护理的支柱，因为溶栓治疗具有 在脑血管脆弱的新生儿中呈高水平。在这个项目中，我们将使用儿科动物的小鼠模型 在有和没有脂多糖(LPS)致敏的情况下，测试中性粒细胞的病理作用 和单核细胞对免疫调节疗法的发展。 目的1：阐明儿科内毒素/卒中时免疫细胞如何突破软膜/神经胶质细胞限制屏障。我们将使用Flow 流式细胞术和单细胞RNA-Seq分析测定免疫细胞的组成和转录组 并检测抗MMP9治疗是否能阻止中性粒细胞内流。 目的2：探讨儿童卒中是否存在两波功能不同的单核细胞浸润。我们 将使用CCR2-Creer小鼠跟踪单核细胞渗透和单细胞RNA-Seq分析，以及阻断 卒中后不同阶段单核细胞的流入解决了这一问题。 目的3：确定儿童术后中性粒细胞脑膜致病性的构成因素。 脂蛋白/中风。我们的RNA-Seq结果表明，中性粒细胞获得了IL-1的一个新家族--IL-36Gamma 家族细胞因子，在脑膜中。我们将验证这些发现，并测试抗IL36R治疗的好处。 该项目的成功完成将有助于深入了解儿童缺血性中风的发病机制。 中性粒细胞/单核细胞靶向免疫调节治疗能否提供更好的临床治疗。

PROJECT SUMMARY (Description) Ischemic stroke affects around 1 in 1600 to 4000 births, has the highest incidence in neonates and infants (< one year of age), and may cause neurological sequalae, including motor and cognitive deficits. Infection and immune responses are a major risk factor for pediatric stroke, but no immune-directed therapies are available. In fact, supportive measures remain the mainstay of pediatric stroke care, since the lytic treatment carries a high in neonates with fragile cerebrovascular vessels. In this project, we will use a murine model of pediatric stroke, with and without lipopolysaccharides (LPS)-sensitization, to test the pathological roles of neutrophils and monocytes towards the development of immunomodulation therapies. Aim 1: To clarify how immune cells breach the pial/glia limitans barrier in pediatric LPS/stroke. We will use flow cytometry and single-cell RNA-Seq analysis to determine the compositions and transcriptome of immune cells in the meninges after LPS/stroke, and test whether anti-MMP9 treatment prevents the neutrophil influx. Aim 2: To test whether there are two waves of monocytic infiltrates with distinct functions in pediatric stroke. We will use CCR2-CreER mice to track monocytic infiltrates and single-cell RNA-Seq analysis, as well as, block the influx of monocytes at different stage after stroke to address this issue. Aim 3: To determine what constitutes the meninges-incurred pathogenicity of neutrophils after pediatric LPS/stroke. Our RNA-Seq results suggest that neutrophils acquire IL-36gamma, a novel family of the IL-1 family cytokine, in the meninges. We will validate these findings and test the benefits of anti-IL36R treatment. Successful completion of this project will shed insights into the mechanisms of pediatric ischemic stroke and whether neutrophil/monocyte-targeted immunomodulation therapies could provide better clinical management.